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ABSTRACT
Objective: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2),
and schwannomatosis (SWN) have not been identified to date. The biomarker working group’s goals
are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers
in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker develop-
ment; and (4) standardize sample collection and methodology protocols where possible to promote
comparison between studies by publishing standard operating procedures (SOPs).
Methods: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and
on biobanking efforts outside these diseases via literature search, defined the need for bio-
markers in NF, and developed recommendations in a series of consensus meetings.
Results: We describe existing biomarkers in NF and report consensus recommendations for SOP
and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and
SWN in decentralized biobanks.
Conclusions: These recommendations are intended to provide clinicians and researchers with
a common set of guidelines to collect and store biospecimens and for establishment of biobanks
for NF1, NF2, and SWN. Neurology® 2016;87 (Suppl 1):S40–S48
GLOSSARY
5-S-CD 5 5-S-cysteinyldopa; ADM 5 adrenomedullin; MIA 5 melanoma inhibitory activity; MPNST 5 malignant peripheral
nerve sheath tumors; NF1 5 neurofibromatosis 1; NF2 5 neurofibromatosis 2; PNF 5 plexiform neurofibromas; REiNS 5
Response Evaluation in Neurofibromatosis and Schwannomatosis; sAXL 5 soluble growth factor receptor Axl; SOP 5
standard operating procedure; SWN 5 schwannomatosis.
The neurofibromatoses—neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwan-
nomatosis (SWN)—are genetically distinct neurocutaneous syndromes that share many features.
All 3 conditions demonstrate wide variability in disease manifestations, and are characterized by
progressive, lifelong, and potentially life-threatening complications. Standard treatment is limited
to surgery for most tumor manifestations. Given the unmet need for nonsurgical therapies, there
have been.20 clinical trials performed between 1993 and 2014 for NF1 and NF2 with varying
measures of response. Few studies have documented evidence of clinical efficacy for investigational
agents.1 To date, no biomarker-driven trials have been performed in NF.
The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International
Collaboration was created in 2011 to define and develop the most informative, reliable, and mean-
ingful endpoints for clinical trials for NF. The REiNS group is composed of several working
groups.2 The biomarker working group, which includes neurologists, oncologists, geneticists,
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pathologists, dermatologists, pediatricians, and
basic scientists, has the goals to (1) define bio-
marker needs in NF1, NF2, and SWN; (2)
summarize existing data on biomarkers in
NF1, NF2, and SWN; (3) outline initial recom-
mendations for sample collection and biomarker
development; and (4) harmonize sample collec-
tion and processing protocols where possible to
allow for data comparison between studies by
publishing standard operating procedures
(SOPs).
This article summarizes the progress toward
these goals. The biomarker group has concen-
trated on biomarkers in blood, urine, and tissue.
Imaging biomarkers are discussed separately by
the REiNS imaging working group.3
METHODS The biomarker group first performed a literature
search, and reviewed and summarized existing data on biomarkers
in NF1, NF2, and SWN. The group then met during a series of
meetings in collaboration with the Children’s Tumor Foundation
(1) to establish SOPs for sample collection of NF tissue specimens
that facilitate data comparison between studies and (2) to develop
a minimal clinical dataset that would accompany each sample.
The working group anticipates that these recommendations will
be updated periodically as new information on biomarkers be-
comes available. Detailed assay protocols will be available on the
REiNS Web site (www.reinscollaboration.org).
RESULTS Biomarkers are used for early detection of
disease or in disease classification (diagnostic biomarkers),
in predicting response or adverse events (predictive bio-
markers), in defining optimal drug dose (metabolic/phar-
macodynamic biomarkers), or in forecasting progression
or recurrence (outcome biomarkers).4 Previous natural
history studies in NF1 and NF2 have clearly demon-
strated a high degree of variability in disease phenotype
and tumor behavior in these conditions.5 This variability
introduces complexity into the identification of valid bio-
markers for NF and schwannomatosis. For example,
a biomarker could potentially correlate with the presence
of the genetic syndrome (e.g., NF1, NF2, or schwanno-
matosis), of a specific tumor type (e.g., gastrointestinal
stromal tumor in NF1), with a nontumor phenotype of
NF (e.g., pain severity in schwannomatosis), with cumu-
lative disease burden (e.g., whole body tumor burden),
with disease progression (e.g., growth of plexiform neu-
rofibroma in NF1), or with malignant transformation
(e.g., malignant peripheral nerve sheath tumor from plex-
iform neurofibroma). Given the overlap in many of these
phenotypes, validating these biomarkers for individual
disease manifestations will require careful phenotyping
of patients.
Diagnostic biomarkers in NF.Historically, NF1, NF2, and
schwannomatosis have been diagnosed using established
clinical criteria. Advances in molecular techniques over
the last 2 decades have led to the availability of genetic
diagnosis for these conditions.6,7 The sensitivity of genetic
analysis for diagnosis of NF depends on the founder
status and the clinical phenotype (segmental vs general-
ized) but ranges from 30% for sporadic schwannomatosis
to .95% for NF1. When a causative genetic alteration
in the NF1, NF2, SMARCB1, or LZTR1 genes is identi-
fied, it can be used as diagnostic biomarker for related
family members. In clinical practice, this information is
used by reproductive endocrinologists for prenatal diagno-
sis or preimplantation genetic diagnosis and by genetic
counselors for presymptomatic diagnosis of family mem-
bers. However, additional diagnostic biomarkers will
undoubtedly be useful to identify patients with specific
disease features, such as plexiform neurofibromas or optic
gliomas.
Outcome biomarkers in NF. Similarly, there is great
variability in clinical outcomes for patients with NF.
For example, while optic pathway glioma occurs in
about 15% of individuals with NF1, only about 1/3
of these tumors are symptomatic, and less will progress
and require active treatment.8 Optic pathway gliomas
will even spontaneously regress without treatment.
This variability in outcome highlights the need to
develop outcome biomarkers for NF disease manifes-
tations. Outcome biomarkers provide evidence about
the patient’s disease outcome independent of any
specific intervention. A validated outcome biomarker
would be valuable to determine the long-term risk for
dermal neurofibromas and malignant peripheral nerve
sheath tumors in patients with NF1, for risk of complete
deafness in patients with NF2, and for risk of severe
chronic pain in patients with schwannomatosis.
Predictive biomarkers in NF.Over the last decade, there
has been an explosion of clinical trials for NF-related
tumors and conditions. The opportunity to study
novel agents in NF opens the possibility of developing
and incorporating biomarker studies into early clinical
trials. To date, clinical trials run through the
Neurofibromatosis Clinical Trials Consortium have
included studies of pharmacodynamic biomarkers and
predictive biomarkers. As drugs with activity against
NF become available, these studies will provide
valuable information about which patients are likely
to require treatment in the future and which are likely
to respond to therapy.
Existing data on biomarkers in NF1, NF2, and SWN.
During development, biomarkers pass through a series
of stages, including early research and development
(exploratory biomarker), demonstration and validation
(probable biomarker), characterization and qualification
(known biomarker), and surrogacy (biomarker can substi-
tute for clinical endpoint). For the neurofibromatoses, all
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biomarkers published to date are considered exploratory;
none has been validated to achieve probable biomarker
status. Thus far, all published biomarker studies have
been performed in the setting of NF1 (table 1); there
are no published data on biomarkers in NF2 or schwan-
nomatosis. These exploratory studies are all limited by
a variety of technical issues such as limited statistical
power, lack of an independent validation set, and lack
of longitudinal data.
Diagnostic biomarkers in NF1.
• Melanoma inhibitory activity (MIA)—In
a study of 42 patients with NF1 and 22 healthy
controls,9 MIA serum levels were significantly
Table 1 Exploratory biomarker studies published for neurofibromatosis 1 (NF1)
Biomarker Correlate with NF patients, n Controls, n Result Reference
Diagnostic biomarkers
MIA NF1 status 42 22 Greater in NF1 than in unaffected controls 9
Tumor load Greater in NF1 with PNF than in NF1 without PNF
MPNST Greater in patients with NF1 with higher tumor burden
No difference between patients with NF1 with or without
MPNST
MIA 5-S-CD NF1 status 25 14 MIA greater in NF1 than in unaffected controls 10
PNF status No difference in MIA between patients with NF1
with or without PNF
Age MIA levels correlate with age
5-S-CD greater in NF1 than in unaffected controls
5-S-CD does not correlate with age
ADM MPNST 32 25 Higher ADM levels in NF1 with MPNST than in NF1
with PNF
11
No difference between patients with NF1 with or
without PNF
Higher ADM levels in patients with NF1 6 PNF than
in controls
IL-6, IFN-g, TNF-a,
EGFR
NF1 status 104 41 Serum concentrations of IL-6, IFN-g, and TNF-a were
significantly higher in NF1 than in healthy controls
14
MPNST status Serum concentrations of EGFR were significantly lower
in NF1 than in healthy controls
IGFBP-1, RANTES NF1 status 104 41 Serum concentrations of IGFBP-1 and RANTES were
significantly higher in patients with NF1 with MPNST
than in those without MPNST
14
MPNST status Serum IGFBP-1 correlated with internal tumor load
Internal tumor load
Fetal antigen 1 NF1 13 177 Statistically significant difference between median values 12
Not able to distinguish between groups
sAXL NF1 diagnosis,
presence of NF1
72 46 Increased in patients with NF1 compared to controls 13
Increased in patients with NF1 with PNF compared to
those without
RASSF1A
methylation
MPNST 20 MPNTS methylated,
12 unmethylated
MPNST with RASSF1 methylated had worse prognosis
than unmethylated, p 5 0.014
15
miR-204 MPNST 12 NF1, 10 NF1 1
MPNST
Downregulation of miR-204 downregulated in MPNST 16
Predictive biomarkers
FOXM1 Survival 38 MPNST High FOXM1 protein expression was predictor of poor
survival for patients with NF1 with MPNST
17
CDK4 Survival 38 MPNST CDK4 copy number gain by aCGH was predictor of
poor survival for patients with NF1 with MPNST
17
Survivin/TK1,
TOP2A
Survival with MPNST 64 NF1 with MPNST Stratifies MPNST into high and low risk 20
Abbreviations: 5-S-CD 5 5-S-cysteinyldopa; aCGH 5 array comparative genomic hybridization; ADM 5 adrenomedullin; EGFR 5 epidermal growth factor
receptor; IFN 5 interferon; IL 5 interleukin; MIA 5 melanoma inhibitory activity; miR 5 microRNA; MPNST 5 malignant peripheral nerve sheath tumors;
PNF 5 plexiform neurofibromas; sAXL 5 soluble growth factor receptor Axl; TNF 5 tumor necrosis factor.
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greater in patients with NF1 (15.2 ng/mL) than
in controls (4.5 ng/mL), in patients with NF1
with plexiform neurofibromas (PNF) than in
those without PNF, in patients with NF1 with
high numbers of cutaneous or subcutaneous
neurofibromas than in those without such tu-
mors, and in patients with NF1 with greater
internal tumor load than in those with low inter-
nal tumor load. In contrast, serum levels of MIA
were not significantly different between patients
with NF1 with and without malignant peripheral
nerve sheath tumors (MPNST). MIA as a bio-
marker for NF1 was also investigated by
another group.10 This group added the anal-
ysis of the metabolite 5-S-cysteinyldopa
(5-S-CD). They found concordant results
with higher MIA levels in 25 patients with
NF1 compared with 14 controls (13.1 vs
9.3 ng/mL) but did not find significantly dif-
ferent levels between patients with NF1 with or
without PNF (15.1 vs 12.0 ng/mL, respectively).
In their study, serum 5-S-CD levels were signif-
icantly higher in patients with NF1 than in con-
trols and did not correlate with age. Hence, MIA
does not appear to be a robust biomarker for
distinguishing unaffected controls from patients
with NF1 or between patients with NF1 with or
without MPNST. Further work is needed to
explore the utility of 5-S-CD to distinguish
between groups.
• Adrenomedullin (ADM)—In a study of 32 patients
with NF1 and 25 control patients,11 serum ADM
levels were significantly greater in patients with
NF1 with MPNST (0.24 ng/mL, n 5 5) than
in patients with NF1 with PNF (0.18 ng/mL,
n 5 17); however, there was significant overlap
in ADM levels between the cohorts. ADM levels
were also significantly higher in patients with NF1
with or without MPNST (0.18 ng/mL, n 5 27)
than in controls (0.07 ng/mL, n5 25). No signif-
icant differences were noted between patients with
NF1 with or without PNF. Although the data for
ADMdata are more promising than those forMIA,
the current data do not indicate that ADM is a reli-
able biomarker in NF1 and further studies are
warranted.
• Fetal antigen 1—In a study of 13 adult patients
with NF1 and 177 adult controls,12 the median
fetal antigen 1 levels were significantly higher in
the serum of patients with NF1 (30.6 ng/mL)
than in control patients (24.9 ng/mL), although
there was considerable overlap between the
groups.12
• Soluble growth factor receptor Axl (sAXL)—
In a study of 72 patients with NF1 and 46
healthy controls, serum levels of sAXL were
significantly increased in patients with NF1
(23 ng/mL) compared with controls (16 ng/
mL). Patients with plexiform neurofibromas
had significantly higher levels of sAXL
(26 ng/mL, n 5 36) than patients with
NF1 without plexiform neurofibromas
(18 ng/mL, n 5 36) although there was still
some overlap between groups.13
• Systematic screen of multiple serum bio-
markers14—The authors evaluated 104 pa-
tients with NF1 and 41 healthy controls and
proposed 4 candidate biomarkers that were sta-
tistically significantly different in patients with
NF1 vs unaffected individuals (interleukin-6,
interferon-g, epidermal growth factor receptor,
tumor necrosis factor–a) and 2 biomarker can-
didates that were statistically significantly dif-
ferent in patients with NF1 with and without
MPNST (insulin-like growth factor binding
protein 1 and RANTES).
• Danielsen et al.15 analyzed the promoter methyl-
ation of RASSF1A in primary tumor. The au-
thors reported significantly different survival
data for 32 patients with methylated or unmethy-
lated RASSF1A at 5 years.
• MiRNA studies in NF1 and non-NF1 MPNSTs
have been performed using cell lines and tissues.
This study identified the downregulation of miR-
204 as a novel diagnostic biomarker and potential
therapeutic target for patients with NF1 with
MPNSTs.16
All the above-mentioned studies were aimed at
identifying diagnostic biomarkers.
Predictive and pharmacodynamic biomarkers.
• Candidate gene alterations in tumor specimens—
Using high-resolution array-based comparative
genomic hybridization in 38 MPNSTs (23 with
NF1 and 15 without NF1), the authors identi-
fied candidate gene alterations that were then
validated at the DNA, RNA, and protein levels.17
Candidate genes in regions of copy number gain
and associated (predicted) with poor survival
included SOX5,NOL1,MLF2, FOXM1, FKBP1,
CDK4, TSPAN31, ERBB2, MYC, and TP53. In
multivariate analysis, FOXM1 protein expression
and CDK4 copy number gain were the most sig-
nificant independent genomic biomarkers for poor
survival in patients with MPNSTs.
• Aurora kinase A, which is important in mitotic
spindle assembly and nonmitotic related cell dif-
ferentiation, is a potential therapeutic target in
MPNSTs. Recent studies in primary MPNSTs
have demonstrated that pharmacologic aurora
kinase inhibition results in MPNST cells
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Table 2 Recommended minimal clinical dataset
Demographics
Date:
Sex male female
Birth month year
Diagnosis of NF1, NF2, or schwannomatosis infancy childhood adolescence adulthood unknown
Inheritance parent affected parent not affected unknown
Mosaicism patient is mosaic patient not mosaic unknown
Germline mutation not tested tested 1 unknown determined: (specify ___)
Clinical status
Status alive deceased
WHO performance status 0 1 2 3 4
Pain not a problem occasional disabling
Treatment directed at tumor no specific therapy chemotherapy surgery radiation targeted therapy (specify) clinical trial (specify)
NF1
‡6 Café-au-lait macules absent present unknown
Skin fold freckling absent present unknown
Iris Lisch nodules absent present unknown
Dermal neurofibromas absent scattered dense unknown
Subcutaneous nodular neurofibromas absent scattered dense unknown
Diffuse dermal neurofibromas absent scattered dense unknown
Spinal neurofibromas not imaged absent 1–3 levels all levels (cervical, thoracic, lumbar, sacral) unknown
Plexiform neurofibromas present absent by MRI absent clinically, but no MRI unknown
Optic glioma unknown absent present, asymptomatic present, symptomatic, not treated present, symptomatic, treated
Heart defect unknown absent present (specify)
Vascular disease unknown absent present (specify)
Puberty onset prepubertal precocious normal late unknown
Stature ,5th centile 5th–95th centile .95th centile unknown
Peripheral neuropathy unknown absent present
Aqueductal stenosis unknown absent present
Long bone dysplasia unknown absent present
Sphenoid dysplasia unknown absent present
Scoliosis unknown absent present
Intellectual disability unknown absent present
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Table 2 Continued
NF1
Learning disability unknown absent present
Attention deficit disorder unknown absent present
Pheochromocytoma unknown absent present
Glomus tumor unknown absent present
MPNST unknown absent present
Glioma (not optic glioma) unknown absent present
GIST unknown absent present
Leukemia unknown absent present
Breast cancer unknown absent present
Other tumors unknown absent present (specify _____)
NF2
Vestibular schwannoma MRI not done absent by MRI unilateral bilateral unknown
Meningioma MRI not done absent by MRI single multiple unknown
Glioma/ependymoma MRI not done absent by MRI present unknown
Spinal schwannoma MRI not done absent by MRI single multiple unknown
Dermal schwannoma unknown absent present
Nonvestibular cranial schwannoma MRI not done absent by MRI present (specify) unknown
Lenticular opacity unknown absent present
Schwannomatosis
Schwannomas (nonvestibular) only by imaging evidence 1 pathologically confirmed 2 or more, at least 1 pathologically confirmed unknown
Number of schwannomas single scattered dense unknown
Vestibular schwannomas not imaged absent by imaging unilateral bilateral unknown
Meningiomas not imaged absent by imaging single multiple unknown
Other schwannomatosis-related tumors (please specify) not investigated absent present unknown
Abbreviations: GIST 5 gastrointestinal stromal tumors; MPNST 5 malignant peripheral nerve sheath tumors; NF1 5 neurofibromatosis 1; NF2 5 neurofibromatosis 2.
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exiting the cell cycle with cessation of
growth.18 The copy number and expression
of the gene product HMMR was found to be
a functional marker of responsiveness to
aurora kinase inhibition. A variety of less
well-defined and reproducible prognosticators
are summarized in a review by Farid et al.19
• Recently, gene expression analysis of 30 MPNSTs
and subsequent immunohistochemical staining
of 64 MPNSTs revealed a composite set of sur-
vivin (BIRC5), thymidine kinase 1 (TK1), and
topoisomerase 2-a (TOP2A) immunohistochem-
ical staining, which stratifies MPNST into high
and low risk20 independent of age, sex, tumor size,
grade, NF1 status, and surgical remission.
• Blakeley et al.21 have detected lower blood circu-
lating levels of hepatocyte growth factor in patients
with NF2 who responded to bevacizumab. This is
the first evidence that a blood biomarker could be
used predictively to stratify patients with NF2 (n5
13) with the highest likelihood of treatment benefit.
RECOMMENDATIONS FOR SAMPLE COLLECTION
ANDMETHODOLOGY The REiNS biomarker group
discussed potential barriers to biomarker research for NF.
These barriers include the low prevalence of NF1, NF2,
and schwannomatosis, which makes coordinated studies
technically difficult and expensive; the extreme variability
of these conditions requires expert clinical researchers to
accurately phenotype patients. Based on this discussion,
the group endorsed the following goals to advance the
study of biomarkers within the NF community:
1. Build a prospective biorepository of curated sam-
ples. The aim would be to collect longitudinal
samples from each patient to facilitate the devel-
opment of early detection and prognostic markers.
2. Standardize tissue collection at participating institu-
tions. The aim would be to collect all tissues using an
identical protocol that meets standards set forth by the
American Association for Cancer Research–Food and
Drug Administration–National Cancer Institute Can-
cer Biomarker Collaborative4 and would be linked via
a shared, anonymized registry (on a Web site). Par-
ticipating sites would share common consent, SOPs,
quality control (see supplemental data on the
Neurology®Web site at Neurology.org), minimal clin-
ical dataset, and database.
3. Annotate samples with an agreed minimal clinical
dataset. The goal is to link anonymously the pheno-
typic data to deidentified samples in the bioreposi-
tory. A proposed minimal clinical dataset developed
at a consensus meeting in October 2014 is shown in
table 2. The group anticipates that modifications of
this dataset may be required in the future to optimize
the utility of biomarker research.
4. Incorporate the decentralized biorepository into ex-
isting biorepositories that are used for diagnostic
purposes. The biomaterial could thus be used for
both diagnosis and research and is not necessarily
restricted to an upfront definition of the amount of
surplus tissue. Patient care takes preference when
allocating the amount of samples used for bio-
marker investigations.
5. Provide open access to deposited biomarkers to
facilitate research. The aim would be to have sam-
ples and data open to all qualified researchers with
approval of an institutional review board. A biorepo-
sitory council would govern database requests.
6. An operational and an executive committee will
govern requests and audit implementation of
SOPs and quality control measures.
7. Incorporate biomarker collection into clinical studies.
When feasible, sample collection should be incorpo-
rated into prospective clinical trials and natural his-
tory studies to help develop pharmacodynamic and
predictive biomarkers.
8. Incorporate biomarker collection into routine clin-
ical visits. Patients receiving routine care should be
invited to participate in prospective sample collec-
tion during routine clinic visits.
RECOMMENDATIONS FOR BIOMARKERS BASED
ON EXISTING DATA
1. Validate individual biomarkers as well as cocktails/
signatures of biomarkers.
2. For ongoing and planned NF trials, studies of
drug metabolism/pharmacodynamic biomarkers
should be drug-specific.
3. For malignant tumors such as MPNST, explore
and validate cDNA, cRNA, and circulating tumor
cells as biomarkers.
4. Validate use of extracellular vesicles (exosomes) based
on encouraging preliminary data as biomarkers of
cancer.22
5. Using candidate approach, focus on the clinically
relevant questions, i.e., total tumor load, presence
of plexiform neurofibroma, evidence of malignant
transformation, and taking into account the statisti-
cal significance in published studies.We recommend
validating the following biomarker candidates in pa-
tients with NF1: BIRC5/TK1/TOP2A immunohis-
tochemistry, ADM, interferon-g, IGFBP-1, and
sAXL.
6. Complement candidate biomarker approach with sys-
tematic unbiased approach. Encourage well-powered
studies using systematic unbiased approaches, includ-
ing genomics (DNA, RNA, miRNA next-generation
sequencing), metabolomics, and proteomics; that is,
further screening with metabolomics, proteomics,
expression arrays, and miRNA.
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